Treatment of patent ductus arteriosus in very preterm infants in China.
10.3760/cma.j.cn112140-20230706-00440
- VernacularTitle:中国极早产儿动脉导管未闭的治疗现状
- Author:
Ai Min QIAN
1
;
Rui CHENG
1
;
Xin Yue GU
2
;
Rong YIN
3
;
Rui Miao BAI
4
;
Juan DU
5
;
Meng Ya SUN
6
;
Ping CHENG
7
;
K L E E shoo K LEE
8
;
Li Zhong DU
9
;
Yun CAO
3
;
Wen Hao ZHOU
3
;
You Yan ZHAO
1
;
Si Yan JIANG
3
Author Information
1. Department of Neonatology, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.
2. National Health Commission (NHC) Key Laboratory of Neonatal Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China.
3. Department of Neonatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China.
4. Department of Neonatology, Northwest Women's and Children's Hospital, Xi'an 710061, China.
5. Department of Neonatology, Beijing Children's Hospital, Capital Medical University, National Center of Children's Health, Beijing 100045, China.
6. Department of Neonatology, the Affiliated Hospital of Qingdao University, Qingdao 266000, China.
7. Department of Neonatology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450018, China.
8. the Maternal Infant Care Research Center (MiCARE), Mount Sinai Hospital, Toronto M5G 1X5, Canada.
9. Department of Neonatology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310051, China.
- Collective Name:Chinese Neonatal Network
- Publication Type:Journal Article
- MeSH:
Infant;
Infant, Newborn;
Male;
Humans;
Female;
Ductus Arteriosus, Patent/drug therapy*;
Infant, Premature;
Cross-Sectional Studies;
Ibuprofen/therapeutic use*;
Infant, Very Low Birth Weight;
Persistent Fetal Circulation Syndrome;
Infant, Premature, Diseases/therapy*
- From:
Chinese Journal of Pediatrics
2023;61(10):896-901
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To describe the current status and trends in the treatment of patent ductus arteriosus (PDA) among very preterm infants (VPI) admitted to the neonatal intensive care units (NICU) of the Chinese Neonatal Network (CHNN) from 2019 to 2021, and to compare the differences in PDA treatment among these units. Methods: This was a cross-sectional study based on the CHNN VPI cohort, all of 22 525 VPI (gestational age<32 weeks) admitted to 79 tertiary NICU within 3 days of age from 2019 to 2021 were included. The overall PDA treatment rates were calculated, as well as the rates of infants with different gestational ages (≤26, 27-28, 29-31 weeks), and pharmacological and surgical treatments were described. PDA was defined as those diagnosed by echocardiography during hospitalization. The PDA treatment rate was defined as the number of VPI who had received medication treatment and (or) surgical ligation of PDA divided by the number of all VPI. Logistic regression was used to investigate the changes in PDA treatment rates over the 3 years and the differences between gestational age groups. A multivariate Logistic regression model was constructed to compute the standardized ratio (SR) of PDA treatment across different units, to compare the rates after adjusting for population characteristics. Results: A total of 22 525 VPI were included in the study, with a gestational age of 30.0 (28.6, 31.0) weeks and birth weight of 1 310 (1 100, 1 540) g; 56.0% (12 615) of them were male. PDA was diagnosed by echocardiography in 49.7% (11 186/22 525) of all VPI, and the overall PDA treatment rate was 16.8% (3 795/22 525). Of 3 762 VPI who received medication treatment, the main first-line medication used was ibuprofen (93.4% (3 515/3 762)) and the postnatal day of first medication treatment was 6 (4, 10) days of age; 59.3% (2 231/3 762) of the VPI had been weaned from invasive respiratory support during the first medication treatment, and 82.2% (3 092/3 762) of the infants received only one course of medication treatment. A total of 143 VPI underwent surgery, which was conducted on 32 (22, 46) days of age. Over the 3 years from 2019 to 2021, there was no significant change in the PDA treatment rate in these VPI (P=0.650). The PDA treatment rate decreased with increasing gestational age (P<0.001). The PDA treatment rates for VPI with gestational age ≤26, 27-28, and 29-31 weeks were 39.6% (688/1 737), 25.9% (1 319/5 098), and 11.4% (1 788/15 690), respectively. There were 61 units having a total number of VPI≥100 cases, and their rates of PDA treatment were 0 (0/116)-47.4% (376/793). After adjusting for population characteristics, the range of standardized ratios for PDA treatment in the 61 units was 0 (95%CI 0-0.3) to 3.4 (95%CI 3.1-3.8). Conclusions: From 2019 to 2021, compared to the peers in developed countries, VPI in CHNN NICU had a different PDA treatment rate; specifically, the VPI with small birth gestational age had a lower treatment rate, while the VPI with large birth gestational age had a higher rate. There are significant differences in PDA treatment rates among different units.
